By Erin Finot, MS, MBA, Vice President, Immuno-Oncology & Cell And Gene Therapy
Over the past ten years, the introduction of immuno-oncology (IO) therapies has brought about a revolutionary change in the treatment of cancer patients worldwide. Biotechnology has also played a crucial role in driving translational science, developing therapeutic platforms, and designing new trials to support the progress of IO treatments. Nevertheless, biotech sponsors venturing into clinical studies for IO therapies must be ready to confront distinctive scientific and operational obstacles.
This white paper reviews IO innovation in cell and gene therapies, as well as five primary operational challenges, including diversity in patient enrollment, and how to plan for success.